Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/15/2025

Hydrocortisone Injection Discontinuation in Infants

Duration-Dependent Risk of Adrenal Suppression

  • The American Academy of Pediatrics and other medical societies imply that corticosteroid-induced adrenal suppression is duration-dependent, and patients receiving courses longer than 14 days are the ones who might benefit from tapering before discontinuation 1
  • After only 2 days of treatment, the HPA axis remains intact and responsive, making abrupt discontinuation safe, as stated by the American College of Clinical Endocrinologists 1, 2

Clinical Context Matters

  • In anaphylaxis management, hydrocortisone is given as a single dose or short course for infants under 6 months, with no tapering protocol specified, according to the American Academy of Allergy, Asthma, and Immunology 3
  • For pediatric septic shock, hydrocortisone doses are used and weaned "as tolerated to minimize potential long-term toxicities," but this refers to courses lasting days to weeks, not 2 days, as recommended by the Society of Critical Care Medicine 4
  • In perioperative stress coverage, children receive hydrocortisone, which is discontinued when enteral intake is established—typically within 24-48 hours—without tapering, as suggested by the American Society of Anesthesiologists 2

Monitoring After Discontinuation

  • Clinicians should monitor for recurrence of the original condition being treated rather than adrenal insufficiency, as advised by the American Academy of Pediatrics 1
  • Inflammation may recur after discontinuing corticosteroid therapy, especially when stopped abruptly, but this reflects the underlying disease process, not HPA suppression, according to the American College of Rheumatology 1

Common Pitfalls to Avoid

  • A 2-day course for acute illness is fundamentally different from chronic glucocorticoid therapy or physiologic replacement for adrenal insufficiency, as stated by the Endocrine Society 2
  • Extending treatment beyond what is clinically necessary to allow for tapering after only 2 days would expose the infant to additional glucocorticoid burden without benefit, as warned by the American Academy of Pediatrics 1
  • Minimizing corticosteroid exposure is particularly important in neonates and young children, given concerns about neurodevelopmental effects with prolonged use, as recommended by the American Academy of Neurology 2, 4

The 14-Day Threshold

  • The evidence consistently identifies 14 days as the approximate threshold where HPA axis suppression becomes a concern, as stated by the American College of Clinical Endocrinologists 1
  • Patients receiving corticosteroids for more than 14 days "might be particularly likely to benefit from a taper before discontinuing and an evaluation of HPA axis function if in doubt," according to the Society of Critical Care Medicine 1